ArticleProbiotics and antimicrobial proteins2026
Effects and Mechanisms of Lactiplantibacillus plantarum G83 on Enterotoxigenic Escherichia coli (ETEC)-Induced Intestinal Inflammation.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactobacillus johnsonii BS15 Alleviates Fluoride-Induced Intestinal Barrier Injury by Regulating the RhoA/ROCK-Mediated Cytoskeletal Remodeling.Probiotics and antimicrobial proteins · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Enterotoxigenic Escherichia coli (ETEC) is a prevalent intestinal pathogen that significantly impacts both human and animal health. G83, isolated from giant panda feces, has demonstrated notable probiotic properties. In this study, C57BL/6 J mice were randomly divided into Control, ETEC, and G83 groups. Experimental included monitoring body weight, assessing fecal occult blood, histopathological examination of ileal tissues, and quantification of antioxidant markers (SOD, T-AOC, MDA) in ileal tissues. Furthermore, real-time quantitative PCR was utilized to determine mRNA expression levels of inflammatory cytokines (TNF-α, IL-17, IL-10), tight junction proteins (Claudin, ZO-1, Occludin), mucin (Muc2), and lysozyme (Lyz-1). Transcriptomic bioinformatics analysis and 16S rRNA sequencing were integrated to characterize host gene expression profiles and gut microbial compositional dynamics, respectively. The results revealed that G83 alleviated ETEC-induced weight loss, reduced fecal occult blood, and mitigated ileal structural injuries. Additionally, G83 significantly enhanced intestinal antioxidant capacity by increasing T-AOC and SOD levels. Mechanistically, G83 downregulated pro-inflammatory cytokines TNF-α and IL-17 and the levels of Muc2 and Lyz1, while upregulating the expression of tight junction proteins ZO-1, Claudin, and Occludin. Transcriptomic analysis suggests that ETEC triggers inflammasome activation and initiates inflammatory responses by significantly upregulating Aim2. Conversely, G83 exerts protective effects by modulating the immune regulatory network-specifically, by significantly downregulating C3 expression to activate the complement system and participating in mucosal immune remodeling. Enrichment analysis reveals that G83 alleviates ETEC-induced intestinal inflammation primarily by inhibiting the NF-κB pathway and enhancing the intestinal IgA immune network. Additionally, 16S rRNA analysis indicates that G83 may improve ETEC-induced alterations in microbial community structure by increasing the abundance of beneficial bacteria (e.g., Lactobacillus), thereby further ameliorating impairment of intestinal microbial barrier function in mice. These findings provide a scientific basis for using G83 to ameliorate ETEC-mediated intestinal inflammation.
Indexed as
Identifiers
40924368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.